In the latest issue of the Quatrefolic 360° collection, discover how the level of folate available can be linked to infertility and how Quatrefolic®, the active form of folate, is the right solution to support conception projects.
Globally, not less than 48 million to 186 million individuals have a fertility issue. Recently, studies have highlighted the importance of folate level and homocysteine status as critical factors in the early stages of human reproduction.
How folate is correlated to fertility?
Women and men experiencing fertility issues can present low folate availability, often linked to the MTHFR enzyme polymorphism.
Preconceptionally folate supplementation seems to have positive reproductive outcomes in natural pregnancies and pregnancies after assisted reproductive technology (ART) treatment.
In women, inadequate folate levels increase homocysteine levels in the blood. and oxidative stress, one of the factors related to the pathogenesis of fertility disorders such as idiopathic infertility, polycystic ovarian syndrome, and endometriosis.
In men, folate is essential for spermatogenesis. Low folate levels in semen can be associated with poor sperm stability and DNA damage.
Quatrefolic® the right choice of folate
Thanks to its bioavailability that bypasses the MTHR polymorphism, Quatrefolic® provides the adequate folate dosage. It does not require the metabolism of the MTHFR enzyme and is ready to enter human metabolism to normalize homocysteine plasma levels.
DISCOVER ALL OUR LATEST NEWS
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event dedicated to exploring the potential of probiotic yeasts. This live session brought together leading experts to present the latest scientific insights and real-world applications of live yeasts in human health.
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by Lesaffre, led by Jose Pinedo Rivera, Product Manager, had the opportunity to present MyCondro™ to an engaged audience of over 250 industry professionals. The session, titled “Keeping Pace with a Changing World: MyCondro™ Disrupts the Chondroitin Sulfate Market,” was well received, sparking interest and conversations around the future of joint health solutions.
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery Calcification: A Randomized, Placebo-Controlled Trial,” were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection, organized by the European Society of Hypertension (ESH), held in Milan in May 23–26, 2025.
